Ultragenyx Pharmaceutical (RARE) EBITDA Margin (QoQ) (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) EBITDA Margin (QoQ) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Ultragenyx Pharmaceutical 2.71 Bn 2.30 Bn 106.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -6,961.00
Dec 31, 2025 5,220.00
Sep 30, 2025 -4,205.00
Jun 30, 2025 3,808.00
Mar 31, 2025 -2,859.00
Dec 31, 2024 2,034.00
Sep 30, 2024 -1,548.00
Jun 30, 2024 7,278.00
Mar 31, 2024 -5,610.00
Dec 31, 2023 5,215.00
Sep 30, 2023 -1,137.00
Jun 30, 2023 1,674.00
Mar 31, 2023 -1,243.00
Dec 31, 2022 10,722.00
Sep 30, 2022 -8,965.00
Jun 30, 2022 1,245.00
Mar 31, 2022 -4,793.00
Dec 31, 2021 -1,297.00
Sep 30, 2021 -1,485.00
Jun 30, 2021 1,205.00